Zavodnick Todd Erik 4
4 · Revance Therapeutics, Inc. · Filed Sep 20, 2017
Insider Transaction Report
Form 4
Zavodnick Todd Erik
Chief Commercial Officer
Transactions
- Award
Common Stock
2017-09-18+95,000→ 95,000 total - Award
Stock Option (Right to Buy)
2017-09-18+35,000→ 35,000 totalExercise: $24.40Exp: 2027-09-17→ Common Stock (35,000 underlying)
Footnotes (2)
- [F1]Represents a restricted stock award (the "RSA"). The shares underlying the RSA shall vest over a period of four years commencing October 15, 2017, with 25% vesting each year on the annual anniversary of the vesting commencement date, subject to Mr. Zavodnick's Continuous Service (as defined in the Issuer's Amended and Restated 2014 Inducement Plan (the "Plan")) through each such vesting date.
- [F2]The shares subject to the stock option shall vest over a period of four years commencing September 18, 2017, with 25% vesting on the annual anniversary of the vesting commencement date and 1/48th vesting each month thereafter over the remaining three years, subject to Mr. Zavodnick's Continuous Service (as defined in the Plan) through each such vesting date.